Skip to content

27/4

Call 1.10.2025-27.4.2026

EP PerMed Partnership call RITC2026: Test and Demonstration of Multimodal Data Approaches for Personalised Medicine (MultiPMData2026) - Joint transnational call to accelerate development of precision medicine

The application opens on October 1, 2025, the deadline for preliminary applications is January 12, 2026, and the deadline for full proposals is April 27, 2026. Business Finland has allocated €2 million in funding for the application, and we can finance companies, research organizations, and welfare areas/HUS. 

 

More information 

Norma Saha
norma.saha (at) businessfinland.fi


Helena Myllyharju
helena.myllyharju (at) businessfinland.fi

The European Partnership for Personalized Medicine (EP PerMed) partnership launched in January 2024. More than 50 partners and financing organisations from different EU countries are involved in the partnership. In Finland, Business Finland participates as a funding partner. The new Research Innovation and Technology Call for Proposals (RITC) 2026 has opened in October with the theme “Test and Demonstration of Multimodal Data Approaches for Personalised Medicine” (MultiPMData2026). The preliminary budget for the call is approximately €13 million, of which Business Finland's grant budget for Finnish applicants is at most €2 million.

Aim of the call

This call (co-funded by EU) aims to bring together enterprises with clinical actors, including healthcare providers, patients, and researchers, to test innovative solutions in controlled real-world settings to address clear needs in managing multimorbidity.
Funding will be granted to projects focusing on the use of multimodal data in personalised medicine approaches, improving the efficient and personalised care of multimorbid patients. Note, that while clinical studies can be funded in this call, larger clinical trials are out of scope. See full details and instructions in the RITC2026 call text.

Consortium

Consortia are required to be international, interdisciplinary and cross-sector. The application for intent must clearly state the personalized medicine perspective of the planned research.

In addition to the RITC2026 criteria, applicant organizations and projects eligible for funding must meet Business Finland's funding criteria, which are outlined in the funding terms and conditions as well as on our website. Business Finland uses grants to fund companies and research organizations in this call. Additionally, funding may be granted to a wellbeing services county or HUS (Helsinki University Hospital), provided that the same consortium includes a Finnish company as another applicant with its own project. According to the principles of the call, Business Finland can fund a maximum of two Finnish organizations per consortium, which is why certain exceptions to our standard criteria are applied (see below). We particularly encourage companies to participate in consortia. The results of public research must be broadly applicable to the business sector. Depending on the applicant organization, Business Finland will use its RD-funding, Co-Innovation, or Co-Research funding services.

Co-Innovation

  • Learn more about funding and requirements: Co-Innovation. Exceptionally, one Finnish research organization and one Finnish company with their own projects are sufficient to form a Co-Innovation consortium. Finnish consortia consisting of two Finnish companies are also treated as Co-Innovation applications.

Wellbeing Services Counties/HUS:

  • Learn more about funding and requirements: Funding for university hospitals. Exceptionally, a wellbeing services county/HUS and one Finnish company with their own projects are sufficient to form a Co-Innovation consortium.

Single Company RDI

Co-Research

  • Learn more about funding and requirements: Co-Research. If two research organizations or one research organization without a Finnish company with its own project apply for funding, the Co-Research funding model is used. A requirement for funding is that at least 10% of the Finnish research organization’s budget must be funded by a company.

Preliminary Schedule (Possible updates to the schedule on the PerMed website)

The call is two-phased:

  • Deadline for pre-proposal submission 12.1.2026 at 14:00 CET.
  • Communication of the results of the pre-proposal assessment and invitation to the full-proposal stage (project coordinator) around mid-March 2026.
  • Deadline for full-proposal submission 27.4.2026
  • Rebuttal stage end of June 2026
  • Communication of the funding decisions to the applicants September 2026
  • Expected project start end of 2026/beginning of 2027

More information

Contact the Business Finland contact person before sending the pre-proposal applications!

Electronic proposals are submitted using the EP PerMed – submission portal. Finnish participants submit a separate application for Business Finland in the second phase of the call. Eligible applicants will be instructed later.

More information about the call and Business Finland requirements:

Research Innovation and Technology Call for Proposals (RITC) 2026 - European Partnership for Personalised Medicine - EP PerMed

Funding terms and conditions - Business Finland